BiondVax is an innovative biopharmaceutical company developing a Universal Flu Vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
BiondVax’s technology utilizes a unique, proprietary combination of conserved and common epitopes from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
BiondVax has successfully completed two Phase II and two Phase I/II clinical trials of the lead product, the Multimeric-001 Universal Flu Vaccine. In all four trials, the vaccine was shown to be safe and immunogenic, successfully stimulating both humoral and cellular immune responses.
Pre-clinical and clinical results support that Multimeric-001 has two potential indications: (1) universal flu vaccine and (2) universal primer for strain-specific flu vaccines for elderly when given in a prime-boost regimen. BiondVax is currently planning a third Phase II trial examining the new priming indication.
